From: Neurologic manifestations of COVID-19 infection in Asia: a systematic review
Author | Study methods | Neurological manifestation/disorder | Number of patients with neurological manifestation/disorder | Total number of patients |
---|---|---|---|---|
Koh JS and colleagues [4] | Prospective multi-center cohort study | Acute disseminated encephalomyelitis (ADEM) and encephalitis | 4 (4.4%) | 90 patients |
Cerebrovascular disorder (AIS/TIA) | 19 (21.1%) | |||
Cerebral venous thrombosis | 4 (4.4%) | |||
Intracerebral hemorrhage | 2 (2.2%) | |||
Peripheral nervous system disorder (mono/polyneuropathy) | 7 (7.8%) | |||
Dysautonomia | 4 (4.4%) | |||
Mao and colleagues [5] | Retrospective, observational study | Dizziness | 36 (16.8%) | 214 patients |
Headache | 28 (13.1%) | |||
Impaired consciousness | 16 (7.5%) | |||
Acute cerebrovascular disease | 6 (2.8%) | |||
Ataxia | 1 (0.5%) | |||
Seizure | 1 (0.5%) | |||
Taste impairment (dysgeusia/ageusia) | 12 (5.6%) | |||
Smell impairment (hyposmia/anosmia) | 11 (15.1%) | |||
Vision impairment | 3 (1.4%) | |||
Nerve pain | 5 (2.3%) | |||
Lu and colleagues [6] | Retrospective multi-center study | Acute symptomatic seizure | 304 (100%) | 304 patients |
Chandrasekaran and colleagues [7] | Case report | Acute ischemic stroke | 1 (100%) | 1 patient |
Kamal YM and colleagues [8] | Case report | Encephalitis | 1 (100%) | 1 patient |
Khalifa and colleagues [9] | Case report | Guillain-Barré syndrome | 1 (100%) | 1 patient |
Wang and colleagues [10] | Case report | Mental abnormalities associated COVID-19 | 1 (100%) | 1 patient |
Kwon and colleagues [11] | Case series | Acute ischemic stroke | 5 (100%) | 5 patients |
Wada S and colleagues [12] | Case report | Guillain-Barré syndrome | 1 (100%) | 1 patient |